A Study to Reduce Persistent Post-mastectomy Pain Using Opioid-free Anesthesia (RELIEF)
A Single-blinded Randomized-controlled Study to Reduce Persistent Post-mastectomy Pain Using Multimodal Opioid-free Anesthesia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study population
- All of patients will undergo mastectomy with or without immediate breast reconstruction.
- 230 patients will be enrolled.
Intervention
- OFA group will be sedated using dexmedetomidine and lidocaine.
- Conventional opioid anesthesia group will be sedated using remifentanil.
Pain screening
- Breast Cancer Pain Questionnaire (BCPQ)
- Pain-detect, HADS, EQ-5D, PHQ-15 (somatic symptom), PCS (pain catastrophizing), BFI (big five inventory), HAM-A&D, Pressure algometry (Pain sensitivity), Quantitative sensory test (pinprick)
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sung Gwe Ahn, M.D.,Ph.D.
- Phone Number: 82220194402
- Email: asg2004@yuhs.ac
Study Contact Backup
- Name: Soong June Bae, M.D.
- Phone Number: 82220193370
- Email: mission815815@yuhs.ac
Study Locations
-
-
-
Seoul, South Korea, 135270
- Recruiting
- Gangnam Severance Hospital
-
Contact:
- Sung Gwe Ahn, MD, PhD
- Phone Number: 82-2-2019-3370
- Email: asg2004@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All of patients will undergo mastectomy with or without immediate breast reconstruction.
Exclusion Criteria:
- Previous history of breast surgery
- Allergy to drug
- Other cancer history
- Underlying psychologic disorder
- Patients with chronic pain requiring pain killers
- Baseline SpO2 <95%
- Left ventricular EF <40%
- Bradycardia as HR <50 bpm
- BMI >35kg/m2
- Pregnant woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Opioid-free anesthesia group
OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
|
OFA group will be sedated using dexmedetomidine and lidocaine.
Other Names:
|
|
Active Comparator: Conventional anesthesia group with opioid
Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
|
Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
chronic breast pain at 1 year after mastectomy
Time Frame: 1 year after mastectomy
|
chronic pain will be assessed by Breast Cancer Pain Questionnaire (BCPQ).
Zero score means absence of persisting breast-related pain.
The minimum and maximum values of pain scale are 0 and 11, respectively.
High score means worse outcome.
Moderating role of preoperative psychosocial factors on the impact of OFA on chronic postoperative pain will be evaluated.
|
1 year after mastectomy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Sensitivity
Time Frame: 1 year after mastectomy
|
The type of pain will be assessed by painDetect Questionnaire (PDQ).
The PDQ comprises 12 items.
The first three assess current pain, strongest pain during the past 4 weeks, and average pain during the past 4 weeks on a 0-10 point numerical rating scale from "none" to "worst imaginable".
|
1 year after mastectomy
|
|
psychological symptoms
Time Frame: 1 year after mastectomy
|
Presence of anxiety and depression symptoms will be assessed by HADS (Hospital Anxiety and Depression Scale) questionnaire.
The range of each symptoms scale is between 0 and 21.
A scale of 0-7 is defined as normal, a scale of 8-10 is defined as borderline, and a scale of 11-21 is defined as abnormal.
High score means worse outcome.
|
1 year after mastectomy
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sung Gwe G Ahn, M.D.,Ph.D., Gangnam Severance Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Postoperative Complications
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Pain, Postoperative
- Chronic Pain
- Breast Neoplasms
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Azoles
- Imidazoles
- Dexmedetomidine
Other Study ID Numbers
Other Study ID Numbers
- 2021-0568-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.